Bioray Laboratories
Bioray Laboratories
Explore linked clinical trials.10 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Clinical Study of Safety and Efficacy of Universal PSMA CAR- T in Refractory CRPC | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, metastatic prostate carcinoma, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 1 | 2026-07-23 | NCT06895811 | |
| Clinical Study of Safety and Efficacy of Enhanced PSMA CAR- T in Refractory CRPC | Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, neoplasm | Active, not recruiting | Early phase 1 | 2026-07-23 | NCT06228404 | |
| Long-term Follow-up Study of BRL-101 for TDT | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, anemia, beta thalassemia, familial hemolytic anemia, hematologic disorder, hemolytic anemia, hereditary disease, inherited hemoglobinopathy, thalassemia | Recruiting | Not stated | 2026-07-21 | NCT06298630 | |
| Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, anemia, beta thalassemia, familial hemolytic anemia, hematologic disorder, hemolytic anemia, hereditary disease, inherited hemoglobinopathy, thalassemia | Active, not recruiting | Phase 1 / Phase 2 | 2026-07-21 | NCT05577312 | |
| Universal CAR-T Cell Therapy for MM | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Not applicable | 2025-12-01 | NCT07248176 | |
| Universal CAR-T Cell Therapy for NHL | Non-hodgkin Lymphoma,B Cell | Recruiting | Not applicable | 2025-11-25 | NCT07248163 | |
| The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma | Non-hodgkin Lymphoma,B Cell | Recruiting | Phase 1 | 2025-11-25 | NCT05741359 | |
| Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System. | CNS demyelinating autoimmune disease, Chronic Disease, Disease Attributes, Myasthenia Gravis, Generalized, Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, Pathologic Processes, Pathological Conditions, Signs and Symptoms, acute transverse myelitis, autoimmune disease, autoimmune disorder of the nervous system, chronic inflammatory demyelinating polyradiculoneuropathy, cranial nerve neuropathy, demyelinating disease, eye disorder, immune system disorder, multiple sclerosis, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, neuromyelitis optica, optic nerve disorder, optic neuritis, paraneoplastic syndrome, peripheral nervous system disorder, polyneuropathy, polyradiculoneuropathy | Not yet recruiting | Early phase 1 | 2025-01-01 | NCT06485232 | |
| Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases | Sjogren syndrome, Skin and Connective Tissue Diseases, Stomatognathic Diseases, Xerostomia, antiphospholipid syndrome, arthritic joint disease, arthropathy, autoimmune disease, connective tissue disorder, dry eye syndrome, eye disorder, immune system disorder, lacrimal apparatus disorder, mouth disorder, muscle tissue disorder, musculoskeletal system disorder, myositis disease, nervous system disorder, neuromuscular disease, rheumatic disorder, rheumatoid arthritis, salivary gland disorder, skin disorder, systemic lupus erythematosus, systemic sclerosis | Enrolling by invitation | Not applicable | 2024-11-20 | NCT05859997 | |
| Long-term Follow-up Study of BHC001 for TDT | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, anemia, beta thalassemia, familial hemolytic anemia, hematologic disorder, hemolytic anemia, hereditary disease, inherited hemoglobinopathy, thalassemia | Recruiting | Not stated | 2024-03-18 | NCT06314529 |